Clinical trial results:
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily

Summary

EudraCT number	2017-002728-26
Trial protocol	Outside EU/EEA
Global end of trial date	29 January 2013

Results information

Result version number	v1 (current)
This version publication date	21 December 2017
First version publication date	21 December 2017

Trial information

Trial identification

Sponsor protocol code	C-12-028

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01698814
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Alcon Research
Sponsor organisation address	6201 S. Freeway, Fort Worth, United States, 76134
Public contact	Ophthalmology Unit, Novartis Pharmaceuticals, +44 0127666733391, Dennis.wong@novartis.com
Scientific contact	Ophthalmology Unit, Novartis Pharmaceuticals, +44 0127666733391, Dennis.wong@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 January 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 January 2013
Global end of trial reached?	Yes
Global end of trial date	29 January 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.

Protection of trial subjects:

Prior to the start of the study, the study protocol, the informed consent and assent documents, patient instruction sheets, the Investigator's Brochure, as well as any advertising materials used to recruit patients were submitted to institutional review boards (IRBs) and independent ethics committees (IECs). The IRB/IECs reviewed all documents and approved required documents; copies of the approval letters were provided to Alcon. Consistent with both the IRB/IEC's requirements and all applicable regulations, the Investigators periodically provided study updates to the IRB/IEC. A patient or parent/legal guardian (if necessary, a legally authorized representative) provided informed consent, and children signed an approved assent form when appropriate. This study was conducted in accordance with Good Clinical Practices (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 October 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 499
Worldwide total number of subjects	499
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	68
Adolescents (12-17 years)	7

Adults (18-64 years)	413
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited from 15 study centers located in the United States.

Pre-assignment

Screening details:

This reporting group includes all randomized and treated subjects (499).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	AL-4943A

Arm description:

AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks

Arm type	Experimental
Investigational medicinal product name	AL-4943A Ophthalmic Solution
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ophthalmic use

Dosage and administration details:

One drop instilled in both eyes once daily for up to 6 weeks

Arm title	AL-4943A Vehicle

Arm description:

AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks

Arm type	Placebo Comparator
Investigational medicinal product name	AL-4943A Ophthalmic Solution Vehicle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ophthalmic use

Dosage and administration details:

One drop instilled in both eyes once daily for up to 6 weeks

Number of subjects in period 1	AL-4943A	AL-4943A Vehicle
Started	330	169
Completed	329	166
Not completed	1	3
Adverse event, non-fatal	-	2

Pregnancy	1	-
Lost to follow-up	-	1

Baseline characteristics

Reporting groups	
Reporting group title	AL-4943A
Reporting group description:	
AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks	
Reporting group title	AL-4943A Vehicle
Reporting group description:	
AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks	

Reporting group values	AL-4943A	AL-4943A Vehicle	Total
Number of subjects	330	169	499
Age categorical Units: Subjects			
2-11 years	47	21	68
12-17 years	4	3	7
18-64	272	141	413
≥65 years	7	4	11
Gender categorical Units: Subjects			
Female	214	111	325
Male	116	58	174

End points

End points reporting groups

Reporting group title	AL-4943A
Reporting group description:	
AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks	
Reporting group title	AL-4943A Vehicle
Reporting group description:	
AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks	

Primary: Adverse Events

End point title	Adverse Events[1]

End point description:

An adverse event was defined as any untoward medical occurrence in a subject administered a study treatment regardless of causal relationship with the treatment. AEs were obtained as solicited comments from the study subjects and as observations by the study Investigator. This reporting group includes all randomized subjects who received study medication.

End point type	Primary

End point timeframe:

An average of 6 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No formal statistical hypothesis testing was planned or conducted.

End point values	AL-4943A	AL-4943A Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	330	169		
Units: Participants				
number (not applicable)				
Deaths	0	0		
Non-Fatal Serious Adverse Events	0	0		
Discontinuations Due to an Adverse Event	0	2		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Adverse Events (AE) were collected for the duration of the study (3 months).

Adverse event reporting additional description:

An AE was defined as any untoward medical occurrence in a subject administered a study treatment regardless of causal relationship with the treatment. This reporting group includes all randomized subjects who received study medication. AEs were obtained as solicited comments from the study subjects and as observations by the study Investigator.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	15.0

Reporting groups

Reporting group title	AL-4943A

Reporting group description:

AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks

Reporting group title	AL-4943A Vehicle

Reporting group description:

AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks

Serious adverse events	AL-4943A	AL-4943A Vehicle	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 330 (0.00%)	0 / 169 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	AL-4943A	AL-4943A Vehicle	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 330 (0.00%)	0 / 169 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No non-serious adverse events occurred above the 5% threshold.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported